CHAGAS ELISA

Results should always be interpreted together with clinical evaluation, epidemiological background, risk factors, immune status, and other diagnostic procedures.

Serological assays are the main diagnostic tools for chronic Chagas disease, where parasitemia is usually low and intermittent. However, serology does not indicate parasite load, disease stage, organ involvement, or clinical severity.

No single serological test should be considered definitive on its own for Chagas disease diagnosis. Confirmation should be based on at least two serological assays using different antigenic compositions or different methodologies.

A reactive result with CHAGAS immunoassays based on recombinant antigens, should ideally be confirmed with a complementary assay based on a different antigenic principle, such as CHAGAS TESA VIRCLIA® IgG+IgM MONOTEST or CHAGAS IFA IgG+IgM.

In samples with discrepant or inconclusive results between recombinant antigen-based assays and native antigen-based assays, a third serological method should be used to support final interpretation.

Immunofluorescence assays such as CHAGAS IFA IgG+IgM may be useful as a complementary native antigen assay, but immunofluorescence interpretation can be more subjective than automated CLIA or ELISA methods and requires trained personnel.

In suspected acute infection, congenital infection, or reactivation in immunocompromised patients, direct diagnostic methods such as microscopy or PCR should be considered, since circulating parasites may be detectable.

Cross-reactions with other parasitic infections, particularly in patients from endemic areas, should be considered when interpreting positive or borderline serological results.

In immunocompromised patients, antibody responses may be atypical, weak, delayed, or difficult to interpret. Negative or borderline serological results should therefore be assessed with caution.

In newborns or infants born to infected mothers, IgG-based serological results must be interpreted carefully because maternal IgG antibodies can be passively transferred. Congenital infection should be evaluated according to specific diagnostic algorithms.

IgG+IgM combined assays detect antibodies against Trypanosoma cruzi, but they do not by themselves distinguish acute, chronic, congenital, or reactivated infection.

TESA-based assays may be useful for patient follow-up because antibody levels against these antigens may correlate with treatment response; however, serological changes after treatment may be slow and should not be used as the only criterion of cure.